3.3. Safety and Adherence Outcomes
renal disease, nausea, constipation
ADVERSE EVENT, RENAL DISEASE
The safety outcomes in terms of the biochemical indicators of renal function, serum electrolytes, plasma protein, metabolic markers, and 24 h urine collection from baseline to 2 weeks and 4 weeks are shown in Adverse events presenting as gastrointestinal symptoms were identified in three (8.6%) patients in the control group and five (13.2%) patients in the HE-LPF group. This was thought to be related to the progression of renal disease (mainly nausea due to uremic toxins) or concomitant medications (mainly constipation due to calcium supplements). In both groups, the patients reported no gastrointestinal-associated symptoms (